Transcript Highlights:

• This standard is issued by the FDA and followed by all blood banks.
• Additionally, while the FDA guidelines for blood donation does include excluding donors with a history
• So, some of this was mentioned earlier, but the FDA strictly regulates blood collection facilities requiring
• Currently, only 39 of Texas's hospitals are registered with the FDA to collect blood.
• And absolutely, we have no concerns that the hospitals that are currently licensed by the FDA to do this

Bills: SB 53, SB53, SB125, SB315, SB379, SB457, SB541, SB599, SB896, SB921, SB963, SB1038, SB1084, SB1330, SB1461

Keywords: voter registration, election procedures, provisional ballot, change of address, residence requirements, mental health, court proceedings, notice requirements, legal filings, electronic documents, autologous blood donation, direct blood donation, blood bank, hospital, Health and Safety Code, physician order, preoperative blood donation, patient blood reserve, transfusion, surgery

Transcript Highlights:

• And that is a prescription medication that is required under FDA requirements.
• It's federally regulated and approved by FDA.
• And in order for a patient... ...federally regulated and approved by FDA, and in order for a patient
• federally regulated and approved by FDA, and in order for a patient to get that, they must have a prescription
• FDA has issued warnings in commingling it with other medications, but also there are dosages that are

Bills: S1082, S1168, S1756, S1156, S1480

Keywords: provider disputes, health plan, dispute resolution, Medicare, Medicaid, healthcare regulation, background screening, athletic coaches, youth sports, criminal history, expungement, Florida statutes, medical freedom, vaccination, ivermectin, healthcare practitioner liability, immunization exemptions, ambulatory surgical centers, patient safety, licensure

Summary: The committee took up several health-related bills. SB 1082, on a statewide provider and health plan claim dispute resolution program, was presented as a way to let providers and insurers use the federal independent dispute resolution process for emergency out-of-network claims under state-regulated commercial plans. A late-filed amendment clarified when providers and health plans could access the state program, and the bill was reported favorably as a committee substitute. SB 1168, which would centralize background screening clearinghouse functions at the Agency for Health Care Administration, also passed as amended after an amendment requiring sealed and expunged records to be included in screenings for qualified entities. Supporters said centralization would improve turnaround times, reduce duplication, and save costs; the sponsor said the bill also addresses coaches’ background screening language from last session. The committee then approved SB 1156, which moves ambulatory surgery center regulation out of the hospital-focused chapter of law into a standalone section, and SB 1480, as amended by a strike-all, which would grandfather certain temporary certificate holders practicing in areas of critical need if federal designation changes affect those areas. Testimony on SB 1480 emphasized continuity of care for patients in underserved communities, and the bill was reported favorably. The final and most heavily debated measure was SB 1756 on medical freedom, which would require state-approved educational materials on childhood vaccines, require practitioners to provide those materials and alternative schedules before vaccination, expand school immunization exemptions to include conscience-based objections, clarify that the Surgeon General cannot order vaccination during a public health emergency, and authorize pharmacists to provide ivermectin behind the counter without a prescription with written information and safeguards. The sponsor argued the bill strengthens parental choice and informed consent. Committee members raised concerns about vaccine-preventable disease risks, immunocompromised children, school outbreaks, and the impact of adding a new exemption. A Department of Health representative said the department would need to provide details on the history of exemption consultations and noted that removing the earlier consultation requirement had not been shown to increase outbreaks. The committee adopted a friendly amendment to give physicians the same liability protection as pharmacists for ivermectin dispensing, but rejected a substitute amendment that would have required a consultation for exemption requests. Public testimony was overwhelmingly opposed to the bill, with physicians, pediatric specialists, cancer advocates, parents of immunocompromised children, and public health groups warning that it would lower vaccination rates and endanger vulnerable Floridians. The bill remained pending after testimony, with the committee continuing to hear public comment.

Transcript Highlights:

• Speaker, I rise today to urge the House to immediately consider and pass the FDA Modernization Act 3.0
• This act was intended to cut the requirements from the FDA that put so many animals in harm's way.
• Unfortunately, under the Biden administration, the FDA did not fully implement this law, limiting its
• This act was intended to cut the requirements from the FDA that put so many animals in harm's way.
• Unfortunately, under the Biden administration, the FDA did not fully implement this law, limiting its

Keywords: U.S. House of Representatives Floor Proceedings on Tuesday, January 20, 2026, 1012, house, all

Transcript Highlights:

• test whether INE can become a safe FDA test whether INE can become a safe FDA approved<00:54:04.800
• It confines activity to FDA-regulated research and future FDA-approved medical use.
• It keeps us firmly within the FDA framework, provides matching funds, protects patients, and ensures
• A designated consortium member must promptly file an investigational new drug application with the FDA
• “It keeps us firmly within the FDA framework, provides matching funds, protects patients, and ensures

Keywords: Public Health and Welfare - Room 216, 25 February, 2026; 3:00 PM, 925, all

Summary: The committee first handled House Bill 612, which had been laid on the table because of questions about section one. Senator Tate explained that section one would allow the state, counties, and municipalities to enter interlocal agreements to provide installation support services on military installations, mainly road and infrastructure work such as paving and dirt work, and that section two would add Coast Guard medics to an existing provision allowing trained military medics to sit for LPN certification. After questions about the breadth of “installation support services,” the committee adopted the motion for title sufficient, due pass, with opposition noted, and the bill was reported to the Veterans and Military Affairs Committee. House Bill 942 was then passed over at Senator McMahon’s request until Tuesday. The committee then took up House Bill 1034, which would allow terminally ill hospital patients to use medical cannabis gummies. The sponsor said the bill is intended to help terminally ill patients who already qualify for medical cannabis but are denied access in hospitals, and that it prohibits smoking or inhalation. Members raised concerns about whether the bill was too broad, whether it would interfere with hospital and physician judgment, possible drug interactions, federal law issues, liability for hospitals and doctors, storage and disposal requirements, and whether hospitals would incur costs or be forced to handle cannabis on their premises. The sponsor responded that the patient’s use would be logged in the chart, that the caregiver is generally responsible for the lockbox and disposal, and that the bill includes language allowing a facility to opt out if compliance would jeopardize federal funding or licensing. The bill’s author also described the measure as arising from a Coast Guard family’s experience in which a terminally ill patient was denied access to medical cannabis at one hospital but allowed at another, and said the goal is to prevent similar denials for terminally ill patients. He said he was not aware of other drugs treated this way in hospitals, but argued that terminally ill patients should have access to most anything they want. The discussion ended with Senator England asking whether changing the bill’s requirement that a facility “shall” allow medical cannabis to “may” allow it would better protect hospitals and preserve discretion, but no final action on House Bill 1034 was taken in the portion provided.

Transcript Highlights:

• In May of 2022, the FDA removed 23 phthalates from use in food packaging.
• In September of 2022, the FDA started a process to review new toxicology and scientific information in
• In May of 2022, the FDA removed 23 phthalates from use in food packaging.
• going on right this is really an FDA going on right this is really an FDA issue<00:24:47.760>
• The administration and the FDA already don't have the strongest track record in tracking things.

Bills: HF44, HF2102, HF2279, HF2280, HF2281

Keywords: HF44, Casey Jones State Trail, Pipestone Trailhead, Currie Loop, Minnesota bonding bill, capital investment, state bonds, bond proceeds fund, Department of Natural Resources, DNR, trail rehabilitation, trail reconstruction, recreational trail, bike trail, hiking trail, infrastructure, state trail, Pipestone, Currie, bonding authorization

Transcript Highlights:

• I think, you know, if we look back in history throughout the FDA and other advisory committees, there
• Almost 50 years later, in 2018, the FDA finally banned them.
• Secretary Rollins and presumptive FDA Director Dr.
• Red Dye No. 3, for example, has been banned in cosmetics for over 30 years, and just last month, the FDA

Bills: SB 25, SB25, SB314

Keywords: attorney ad litem, indigent parents, parent-child relationship, legal representation, Texas Family Code, court procedures, nutrition, health standards, food labeling, education, dietary guidelines, medical education, food safety, school meals, child nutrition, food additives, public health, 1185, senate, all

Transcript Highlights:

• And then under current FDA requirements regarding dense breast tissue, it says breast tissue can decide
• And then under current FDA requirements regarding dense breast tissue, it says breast tissue can decide
• aims to ensure patients receive the most current scientifically vetted information required by the FDA
• Obviously, you know, policymakers may decide that they want... ...to the FDA requirement.
• Obviously, you know, policymakers may decide that they want to reference the FDA requirement.

Bills: SB1086, SB1193, SB1318, SB1345, SB1346, SB1451, SB1496, SB1611, SB1630, SB1631, SB1632, SB1672

Keywords: reimbursement, healthcare, laboratory services, noncontracting providers, Arizona health care cost containment, personal identifying information, PII, privacy, confidential records, public records exemption, commercial disclosure, data privacy, licensure, certification, health professions, health care licensing, Arizona Department of Health Services, ADHS, emergency medical care technician, EMCT

Summary: The committee first approved the February 4 minutes and then heard Senate Bill 1086, which would require AHCCCS contractors to reimburse non-contracting providers for certain laboratory services when a member was referred by a contracting provider, and would bar prior authorization for diagnostic services and retaliation tied to such referrals. AHCCCS testified neutral but warned the prior-authorization ban could increase utilization and create fiscal and federal compliance concerns. The committee adopted the Warner amendment limiting non-contracting reimbursement to no more than contracting-provider rates, then passed SB 1086 as amended on a 4-2 vote. The committee next took up Senate Bill 1611, an emergency measure to require AHCCCS to contract with an administrative services organization for program integrity and case management functions for the American Indian Health Plan, while keeping AHCCCS ultimately responsible. The chair’s amendment expanded the ASO’s duties to include provider support, quality improvement, and data analytics, removed AHCCCS claims payment authority, added more tribal observers, and exempted IHS and tribal facilities. Testimony strongly supported reforming the system after fraud and overcorrection harmed Native members and providers, but AHCCCS raised concerns about the fast timeline, possible duplication of fraud-fighting functions, and the need for 45 days of tribal consultation. The committee adopted the amendment and passed SB 1611 as amended on a 5-2 vote. Senate Bill 1630 would create a Medicaid-funded home and community-based services program for adults with serious mental illness, capped initially at 250 members under the Angius amendment, with semiannual reporting and a process for future expansion only if costs are reduced or neutral. Supporters said the bill would help the sickest SMI patients avoid repeated hospitalizations, jail, and homelessness, and could save the state general fund by shifting costs to federal Medicaid funding; AHCCCS was neutral and said it was finalizing the fiscal estimate. The committee adopted the amendment and passed SB 1630 unanimously. The committee also passed SB 1193, protecting emergency medical care technician personal information from disclosure; SB 1318, repealing an outdated state dense-breast notification requirement to align with FDA language; and SB 1345, restricting anonymous complaints against health care institutions, though AHCCCS warned that federal law may still require investigation of complaints from any source and that the bill could reduce reporting and invite litigation.

Transcript Highlights:

• That was FDA approved by the science that we did at Moffitt.
• We led the clinical trials at Moffitt that led to FDA approval of that.
• We led the clinical trials at Moffitt that led to FDA approval of that.
• We’ll set the FDA.
• We’re already meeting with the FDA to set the FDA standards for approval of this therapy.

Summary: The Health Care Budget Subcommittee held a panel discussion on Florida’s cancer research and funding programs, including the Casey DeSantis Cancer Research Program, the Florida Cancer Innovation Fund, the James and Esther King Biomedical Research Program, the Bankhead-Coley Research Program, and Live Like Bella. Dr. Ladapo and leaders from Moffitt, Sylvester/University of Miami, UF Health, and Mayo Clinic described how state funding has helped Florida’s four NCI-designated cancer centers expand research, recruit faculty, increase clinical trials, and build collaborations. They emphasized that the programs are intended to improve cancer care statewide, support innovation, and encourage more institutions to pursue NCI designation. The Governor’s budget recommendation was noted as including additional funding, and members asked about the cost and requirements of becoming NCI-designated and eventually comprehensive. Panelists said NCI designation requires major infrastructure, compliance, research, and training investments, with de novo development estimated at about $1 billion. They described Florida’s collaborative model as unusual nationally, with annual symposia, shared pilot funding, and joint projects across the four centers. Members also asked about rural access, home-based care, and recruitment/retention. Mayo described its “Cancer Care Beyond Walls” home-treatment model and said it could expand to rural counties within months; Moffitt and UF discussed mobile screening, satellite sites, and affiliations with local hospitals and practices. Several members raised concerns about workforce shortages, licensure delays, and the need to reach underserved areas. The discussion also covered outcomes, data reporting, and the broader economic impact of the cancer centers. Panelists cited growth in jobs, federal research funding, and clinical trial enrollment, and highlighted advances in immunotherapy, CAR-T, TIL therapy, carbon ion therapy, AI-driven screening, and the firefighter cancer initiative. They said the Florida Cancer Data System is being expanded to track recurrence and quality-of-life measures. Members also asked about philanthropy, medical tourism, and federal funding risks, including possible indirect cost reductions that could affect research budgets. The meeting ended with general support for continued investment, while some members noted an ongoing policy debate over whether future cancer research dollars should be concentrated in the four NCI centers or spread more broadly across the state.

Transcript Highlights:

• I'm an FDA regulatory consultant, so I have filed hundreds of PMTAs. I know this.
• Which is why vape products from China have to be FDA approved, and there are no FDA-approved products
• With some of those discussions, but they require FDA approval, and there are zero FDA-approved products

Bills: SB2024, SB227, SB268, SB1467, SB1580, HB5537, SB1313, SB1677, SB918, SB331, SB2207, SB2721

Keywords: e-cigarettes, marketing prohibition, youth protection, criminal penalties, public health, school funding, education reform, state budget, property taxes, equity in education, health care, licensing, complaint procedure, disciplinary action, law enforcement, death records, vital statistics, healthcare, trauma facility, Medicaid

Transcript Highlights:

• vast variety of professionals, including members of the Board of Dentistry, members of the ADA, the FDA
• vast variety of professionals, including members of the Board of Dentistry, members of the ADA, the FDA
• In addition to the FDA opposing dental therapy legislation, In addition to the FDA opposing dental therapy
• I've been a member of the FDA, Florida Dental Association, since I got out of school 22 years ago.

Summary: The Health Professions and Programs Subcommittee heard and advanced three bills. HB 21 would create a new licensed profession of dental therapy under the Department of Health and Board of Dentistry, allowing trained dental therapists to provide a limited scope of care under a supervising Florida-licensed dentist through a collaborative management agreement. Sponsor Rep. Cheney argued the bill would help address severe dental shortages and improve access in underserved areas; opponents from the Florida Dental Association and oral surgery groups warned that the bill would allow irreversible procedures by less-educated providers and could compromise patient safety. Supporters, including dentists, hygienists, and community health center leaders, said dental therapists would expand access and free dentists to handle more complex care. An amendment was adopted to require proof of local anesthesia training, adverse-incident reporting, and updated background screening language. The bill was reported favorably as amended by a 14-1 vote. The committee then considered HB 27, which creates the Social Work Licensure Interstate Compact to allow licensed social workers to practice across member states, including through telehealth, and to help military families and address workforce shortages. Supporters from the National Association of Social Workers and other advocates said the compact would improve mobility, reduce administrative burdens, and expand access to mental health services, especially in underserved and rural areas. A technical amendment restoring model language and setting an effective date of July 1, 2025 was adopted, and the bill was reported favorably as amended on a 15-0 vote. Finally, the committee heard HB 29, the public-records companion to the social work compact, which creates exemptions needed for compact compliance and allows the compact commission or its committees to meet in closed session when discussing information exempt under law. After a technical amendment authorizing closed meetings for exempt matters was adopted, the bill was reported favorably as amended on a 15-0 vote. The meeting then adjourned.

Transcript Highlights:

• Ibogaine has not yet been approved by the FDA, and even though it is not approved, the FDA is likely
• This drug is not yet FDA approved. It needs to get FDA approved.
• <01:46:33.840> It<01:46:34.159> needs drug is not yet FDA approved.
• It needs drug is not yet FDA approved.
• There are many to get FDA approved.

Keywords: 1. Call to Order and Roll Call – 00:00:00 2. Approval of Minutes – 00:01:32 3. Getting to Know the Foundation for a Healthy Kentucky – 00:02:26 4. Healthy Kids Clinic – 00:26:58 5. Pharmacy Payment Parity – 00:56:36 6. Ibogaine – 01:17:37 7. Consideration of Referred Administrative Regulations – 01:53:05 8. Adjournment – 01:53:19, 958, all

Summary: The committee first approved the prior meeting minutes and recognized Eric Clark for his service, noting this may be his last meeting before he leaves state government. The main presentation was from Allison Adams, president and CEO of the Foundation for a Healthy Kentucky, who described the organization’s history, nonpartisan mission, and focus on health equity, prevention, and upstream policy solutions. She said Kentucky’s poor rankings in chronic disease, preventable hospitalizations, and life expectancy show the need to shift resources toward prevention and community-driven strategies rather than relying mainly on treatment after people become sick. Adams emphasized leading health indicators, arguing that lawmakers should track actionable measures such as quit attempts and smoke-free policies instead of only lagging indicators like disease rates and mortality. In response to questions, she said accountability should be shared across communities and systems, with possible incentives and disincentives tied to outcomes, and she supported creating a public data utility or dashboard, ideally with university partners, to help legislators and communities monitor progress. She also cited examples of accountable health community models and said Kentucky could adapt similar approaches. The committee then heard from Meade County Schools Superintendent Mark Martin and district health coordinator Karen Kotche about the Healthy Kids Clinic partnership with Cumberland Health. They described a seven-year effort that led to full implementation in the district, which now has a nurse in every school and a nurse practitioner, allowing services such as sports physicals and other clinic functions to be provided on campus. They said the program has been a strong investment for students and the community and began explaining how the district built the partnership after earlier efforts and delays, including the pandemic.

Transcript Highlights:

• Those are currently legal today through the FDA. Those are currently legal today through the FDA.
• Epidiolex is an FDA-approved CBD prescription.
• They advise THC products as medicine despite lacking FDA approval. ...as medicine despite lacking FDA
• It protects legitimate hemp farmers and FDA-approved medications.
• Approved by the FDA.

Bills: SB 5, SB 11, SB 12

Keywords: disaster relief, flood preparedness, emergency funding, local government support, meteorological forecasting, human trafficking, trafficking victim, compelling prostitution, affirmative defense, criminal defense, coercion, force fraud or coercion, sexual exploitation, victim protection, Penal Code, Texas criminal law, prosecution, party liability, affirmative defense statute, survivor rights

Summary: The Senate Committee on State Affairs took up Senate Bill 5, which Senator Perry described as a ban on intoxicating THC consumer products while preserving legal CBD, CBG, hemp seed, hemp seed protein powder, and hemp seed oil products. Perry argued that most retail THC products are already illegal under federal law, that the industry has used loopholes and misleading labeling to sell high-potency products, and that regulation would be ineffective because chemists can quickly alter formulations. He also said the bill would steer people with medical needs toward the Texas Compassionate Use Program (T-Cup), which he and other supporters described as the proper physician-guided alternative. Committee members and witnesses repeatedly discussed the distinction between legal hemp-derived products and intoxicating THC products, and Perry said the bill would not touch non-consumable hemp uses such as fiber and clothing. Invited testimony came from law enforcement and medical witnesses who supported the bill. Texas Police Chiefs Association representative Steve Dye, Kaufman County District Attorney Early Wiley, and Chambers County Sheriff Brian Hawthorne all said regulation would be too costly, too complex, and ultimately unenforceable, while a ban would be clearer and easier to enforce. They cited overloaded DPS labs, the need for expensive private testing, limited police and prosecutor resources, and the difficulty of keeping up with constantly changing cannabinoids and out-of-state products. Hawthorne and Wiley described raids and investigations involving warehouses, retail stores, cash seizures, and products they said were marketed to young people and often mislabeled or imported from other states. They also said the bill would help law enforcement by creating a clearer legal line and protecting legitimate CBD/CBG businesses. Dr. Lindy McGee, speaking for the Texas Medical Association and Texas Pediatric Society, testified that retail THC products pose serious risks to children and adolescents, including addiction, impaired brain development, psychosis, suicide attempts, self-harm, accidental toddler ingestions, and possible long-term cognitive effects. She said there is no effective medication treatment for THC addiction comparable to nicotine cessation tools, and she supported restrictions such as child-resistant packaging, no marketing to minors, and age limits, while opposing criminal penalties for possession by minors. Senators asked follow-up questions about brain development, memory, dementia risk, pregnancy, and cardiovascular effects. No vote was taken during the portion provided, and the committee continued with invited testimony and questions.

Transcript Highlights:

• them a license, make sure they have a license from the DEA and that they have been inspected by the FDA
• . ...they have been inspected by the FDA.
• Frequently, we find problems in those facilities where the FDA has identified bacteria and so on and
• ...process down, and we feel we can't issue a license to a business that has had problems with the FDA

Bills: SB36, SB39, SB40, SB12, SB29, SB121, SB131, SB12

Keywords: competitive bidding, procurement, disclosure statements, state contracts, contract protest, board governance, occupational licensing, Sunset Law, public accountability, training requirements, SB40, Houston/Hunter Act, firearm hold agreement, gun storage, temporary firearm storage, firearms dealer, federal firearms licensee, FFL, civil immunity, gun owner

Transcript Highlights:

• They face no additional tax impositions, no host community agreements, no recall process, no FDA testing
• No recall process, no FDA testing requirements, no age limits, and, as Commonwealth Beacon has reported
• that product ingestible products like food and beverage that contain THC had not been approved by the FDA
• These warning labels serve as reminders that these products are not FDA approved, identify potential
• The FDA prohibits any sort of hemp edibles, and so does the DPH here.

Keywords: 995, all

Summary: The Joint Committee on Cannabis Policy held a hearing on a broad set of cannabis and hemp bills, with the chairs opening by emphasizing unfinished work on equity, public health, safety, and market stability. The committee heard testimony on House Bill 146, which would create more efficient cannabis testing standards by increasing batch sizes, reducing or eliminating some environmental testing, standardizing lab reporting, and requiring annual scientific review and public data reporting. Industry witnesses, including a representative of the Massachusetts Cannabis Coalition, cultivators, and a testing lab owner, said current testing rules are overly burdensome, costly, and inconsistent, and argued the bill would lower compliance costs while preserving consumer safety. A testing lab witness also said some operators switch labs to obtain higher THC results or pass contaminated batches, and urged greater transparency and better sampling protocols. A major portion of the hearing focused on intoxicating hemp and related bills that would bring hemp-derived intoxicating products under a stronger regulatory framework. Legislators and industry witnesses described products sold in gas stations, smoke shops, and convenience stores as often untested, not age-gated, and sometimes mislabeled or far above the federal hemp THC threshold. Testimony from attorneys and cannabis business leaders said states can regulate these products more strictly under the Farm Bill’s non-preemption language, and pointed to New Jersey and other states as possible models. Some witnesses and committee members stressed that any new rules should avoid harming non-intoxicating CBD businesses or lawful hemp farmers, while others argued that the products are effectively cannabis and should be regulated like cannabis for licensing, testing, age limits, and taxation. The committee also heard extensive public-health testimony in support of bills S. 95, S. 96, S. 97 and their House counterparts H. 191, H. 192, and H. 193. Parents, advocates, and public health professionals urged stronger warning labels, THC potency caps, and improved data collection on cannabis-related harms, citing cannabis-induced psychosis, addiction, anxiety, and youth exposure to high-potency products. Several witnesses said Massachusetts has not done enough to track health outcomes or warn consumers, and referenced other jurisdictions such as Connecticut, Vermont, Colorado, Canada, and Quebec as examples of stronger limits or warnings. No votes or formal actions were taken during the hearing; the committee primarily received testimony and questions.

Transcript Highlights:

• On the diagnostic side, a new blood test was approved by the FDA just this year that helps diagnose the
• A blood test, the FDA just approved just a week ago, Ago, the FDA just approved that blood tests can
• FDA has approved it, but CMS has to write the rules to enact it, and that can take some 12 to 18 months
• I like the FDA thing that just came out.
• It's been approved by the FDA. Let me interrupt real quick. You said CMS before.

Transcript Highlights:

• This is often required by the FDA to ensure reduced complications and improve patient outcomes.
• We have an FDA mandate to teach them the safe and effective use of our products and techniques, and we
• I don't mean to be disrespectful, but your need for bodies to practice on is the FDA.
• We have an FDA regulatory obligation to make sure that we train surgeons on the use of our products,
• aspect that we've been talking about is for training and education once a device is approved by the FDA

Bills: SB2024, SB227, SB268, SB1467, SB1580, HB5537, SB1313, SB1677, SB918, SB331, SB2207, SB2721

Keywords: e-cigarettes, marketing prohibition, youth protection, criminal penalties, public health, school funding, education reform, state budget, property taxes, equity in education, health care, licensing, complaint procedure, disciplinary action, law enforcement, death records, vital statistics, healthcare, trauma facility, Medicaid

Transcript Highlights:

• <04:09:15.920> and operations between the FDA and operations between the FDA and regulatory
• <04:14:40.560> And could come to FDA for approval. And could come to FDA for approval.
• It was the first program within the FDA.
• <04:26:12.880> This to do with the FDA approval for it.
• This to do with the FDA approval for it.

Keywords: U.S. House of Representatives Floor Proceedings on Monday, December 1, 2025, 1012, house, all

Transcript Highlights:

• and provides that health insurance may not exclude coverage for drugs that are not approved by the FDA
• That's great for 1997 because in 1997 the FDA only approved two to four drugs per year.
• Right now, the FDA, we have numerous more cancer drugs Available to us, number one.
• Is that FDA or some other entity? Madam Chair, that's a great question.
• I want to say that that has to be someone in the pharmacy chain of command, maybe FDA.

Keywords: 908, all

Summary: The committee met to review the history and current treatment of North Dakota health insurance mandates, with presentations from Blue Cross Blue Shield of North Dakota, Sanford Health Plan, the Public Employees Retirement System (PERS), and the Insurance Department. The discussion focused on how mandates apply differently to fully insured, self-funded, ACA, Medicaid, and PERS plans; how the state’s benchmark plan and federal essential health benefits affect coverage; and how the existing process requires cost-benefit analysis and, for certain measures, a PERS pilot period before broader application. Presenters also reviewed the long list of existing state mandates, including provider, beneficiary, and coverage requirements, and noted that many were enacted decades ago and have not been revisited despite changes in medical evidence and treatment options. Witnesses from the carriers argued that mandates should be reviewed periodically because some are outdated, can create unintended costs, and may not align with current medical guidance. Examples cited included PSA screening, off-label drug coverage, prior authorization rules, step therapy, and cost-sharing provisions for mental health and substance use treatment. They emphasized that carriers often cover services without a mandate when supported by clinical evidence, and that mandates can shift costs to employers and employees, especially in the fully insured small-group market. They also suggested possible policy improvements such as clearer mandate definitions, better transparency around cost-benefit analyses, a regular 10-year review of mandates, and more timely submission of proposals through the interim process. PERS and the Insurance Department highlighted a recurring tension over what counts as a mandate and when a measure triggers the state’s defrayal obligation under federal law. PERS described its interim committee process, the April 1 deadline for fiscal-impact proposals, and the limited pilot program used for certain measures, noting that only a few bills have gone through the full pilot process. The Insurance Department explained that it views new benefit mandates through the lens of the ACA benchmark plan and essential health benefits, distinguishing true new benefits, such as infertility coverage, from changes to existing benefits, such as telehealth or insulin cost-sharing caps. No votes were taken on policy changes; the meeting was informational, with members asking questions about costs, applicability, transparency, and whether a periodic mandate review should be established.

Transcript Highlights:

• There's no FDA approval.
• If these products are indeed medicinal, they should go through the FDA approval.
• The FDA says that 10 mg of synthetic THC can trigger psychosis.
• According to the FDA, just 10 milligrams of THC can trigger psychosis.
• As regards to the FDA... The FDA has only approved one CBD medication, Epidiolex, for children.

Bills: HB28, SB3, SB 3

Keywords: hemp regulation, consumable products, cannabinoids, state health, youth protection, licensing fees, criminal offenses, flash flood, flood warning, outdoor warning siren, emergency alert, disaster preparedness, flood mitigation, Hill Country floods, Texas Water Development Board, municipalities, counties, local government mandate, public safety, grant program

Transcript Highlights:

• that's required to deal with the FDA.
• FDA.
• I should say that the FDA has to strike a balance between protecting the population.
• One of the benefits that we have is a very productive relationship with the FDA.
• We have a dedicated FDA team. We currently have 380 investigational new drugs.

Bills: SB1, SB 1

Keywords: appropriations, budget, state funding, education, healthcare, infrastructure, campground safety, youth camp regulations, flood safety, emergency evacuation, health and safety standards, 1185, senate, all